Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Samalin

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trialDavid Malka, Eric François, Frédérique Penault-Llorca, et al.
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
International Journal of Cancer|November 1, 2023
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resectionAbderaouf Hamza, Julien Masliah-Planchon, Cindy Neuzillet, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
Eclinicalmedicine|November 11, 2024
Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trialAntoine Adenis, Arlette Da Silva, Meher Ben Abdelghani, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2022
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studiesMorgane Stouvenot, Aurélia Meurisse, Angélique Saint, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2019
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trialDavid Malka, Eric François, Frédérique Penault-Llorca, et al.
The Lancet. Oncology|July 26, 2018
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 studyStefano Kim, Eric François, Thierry André, et al.
International Journal of Cancer|November 1, 2023
Pathogenic alterations in PIK3CA and KMT2C are frequent and independent prognostic factors in anal squamous cell carcinoma treated with salvage abdominoperineal resectionAbderaouf Hamza, Julien Masliah-Planchon, Cindy Neuzillet, et al.
Therapeutic Advances in Medical Oncology|December 17, 2020
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinomaStefano Kim, Aurélia Meurisse, Laurie Spehner, et al.
Eclinicalmedicine|November 11, 2024
Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trialAntoine Adenis, Arlette Da Silva, Meher Ben Abdelghani, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
BMC Cancer|August 27, 2017
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)Stefano Kim, Marine Jary, Thierry André, et al.
Pageof 7